2. Academic Validation
  3. Eltrombopag restores proliferative capacity and adipose-osteogenic balance of mesenchymal stromal cells in low-risk myelodysplastic syndromes

Eltrombopag restores proliferative capacity and adipose-osteogenic balance of mesenchymal stromal cells in low-risk myelodysplastic syndromes

  • Eur J Pharmacol. 2024 Dec 15:985:177086. doi: 10.1016/j.ejphar.2024.177086.
Minghua Hong 1,  Juan Guo 1,  Youshan Zhao 1,  Luxi Song 1,  Sida Zhao 1,  Roujia Wang 1,  Lei Shi 1,  Zheng Zhang 1,  Dong Wu 1,  Qi He 1,  Chunkang Chang 2
Affiliations

Affiliations

  • 1 Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
  • 2 Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China. Electronic address: changchunkang@sjtu.edu.cn.
PMID: 39481629 DOI: 10.1016/j.ejphar.2024.177086
Abstract

In low-risk myelodysplastic syndromes (MDS), the proinflammatory signaling is excessive, and the proliferation and differentiation potentials of mesenchymal stromal cells (MSCs) are strongly impaired. Eltrombopag (ELT) has been demonstrated recently effective and relatively safe in low-risk MDS with severe thrombocytopenia. However, its impact on the MDS-MSCs has not been investigated in any detail. Here, for the first time, we investigated the changes induced by ELT in MSCs' viability, proliferation, Apoptosis, senescence, multilineage differentiation properties, and stem cell support capacity in low-risk MDS patients. We demonstrated that ELT may act on improving the impaired inflammatory profile and reactivating the downregulated canonical Wnt signaling pathway in low-risk MDS, and also restoring the self-renewal capacity and the balance in adipose-osteogenic differentiation of MDS-MSCs.

Keywords

Eltrombopag; Mesenchymal stromal cells; Myelodysplastic syndrome; Osteogenic differentiation; WNT; cGAS-STING.

Figures
Products